BB102 / BroadenBio - LARVOL DELTA

The highly selective and potent reversible-covalent FGFR4 inhibitor, BB102, induces targeted-protein degradation through lysosomal autophagy (AACR 2026) - "BB102 is a degrader of FGFR4 with highly selective and potent reversible-covalent FGFR4 kinase inhibition. BB102 has remarkable antitumor activity in mice bearing HCC tumor xenografts. It is permeable to BBB."

Colorectal Cancer • Gastric Cancer • Hepatocellular Cancer • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor • ABCB1 • FGF19 • FGFR4

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor effective in multiple xenograft tumor models (AACR 2024) - "BB102 is a highly selective and potent reversible-covalent FGFR4 inhibitor with promising efficacy in high expression of both FGF19 and FGFR4, and/or FGFR4 mutated tumor models and good safety in preclinical studies. The phase I study of BB102 is in progress."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • FGF19 • FGFR4

A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Broadenbio Ltd., Co.

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

BB102-ST-Ⅰ-02: A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Broadenbio Ltd., Co. | Trial completion date: Jul 2025 ➔ Dec 2026 | Trial primary completion date: Jan 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Solid Tumor

A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: BrodenBio Co., Ltd.

New P1 trial • Oncology • Solid Tumor • FGF19 • FGFR4